FDA
24th July 2018

FDA Advisory Committee Split on Indications for Achaogen’s Plazomicin

On May 2nd, 2018 the Antimicrobial Drugs Advisory Committee convened to review new drug application (NDA) 210303.

FDA Advisory Committee Split on Indications for Achaogen’s Plazomicin

On May 2nd, 2018 the Antimicrobial Drugs Advisory Committee convened to review new drug application (NDA) 210303, for plazomicin, sponsored by Achaogen Inc. Plazomicin is an aminoglycoside antibacterial drug proposed for in the treatment of complicated urinary tract infections (cUTI) and blood stream infections (BSI) in patients 18 years or older, with limited or no alternative treatments. Plazomicin produces a concentration-dependent bactericidal effect through the inhibition of protein synthesis. The proposed starting doses were 15 mg/kg daily for patients with creatinine clearance (Clcr) of greater than 60 mL/min; 10 mg/kg daily for those with Clcr 30 – 60 mL/min and 10 mg/kg every other day for those with CLcr 15 – 30 mL/min.

Plazomicin was evaluated in six phase I studies , one phase II study and one phase III clinical study. The phase II study and one phase III study were conducted for cUTI. The medication was deemed to be non-inferior to a comparable antibiotic in the cUTI study.

There were 2 voting questions presented to the panel. First, the panelists were asked whether the applicant provided substantial evidence of the safety and efficacy of plazomicin for cUTI in patients with limited to no treatment options –  voting 15 (Yes) to 0 (No). Unanimously, the panel indicated that animal studies supported efficacy and clinical data did not show a pattern of serious adverse events. The panel also recommended post marketing safety studies and labeling to provide guidance for therapeutic drug monitoring.

During the second vote, the panel was asked whether the safety and efficacy data presented for plazomicin were adequate for BSI. The committee voted 4 (Yes) to 11 (No). Members who voted yes, said that the study showed some efficacy and safety for those with limited or no treatment options. Members who voted no, were concerned with the very small sample size and inadequacy of the non-inferiority analysis as a basis for approval.

The agency is not obligated to follow its panel’s recommendation, but normally does so. On June 26th plazomicin was approved for cUTI treatment by the FDA. The BSI indication was not approved.

ISS has almost two decades of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net

This post was authored by Sami Mourad. Sami is a summer intern at ISS and a 3rd year pharmacy student at the Rutgers University Ernest Mario School of Pharmacy

 

Do you have an upcoming Advisory Committee Meeting?

  • This field is for validation purposes and should be left unchanged.

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us